Avalo Therapeutics (AVTX) Return on Sales (2016 - 2025)
Avalo Therapeutics filings provide 10 years of Return on Sales readings, the most recent being 2.33% for Q4 2025.
- On a quarterly basis, Return on Sales fell 48.0% to 2.33% in Q4 2025 year-over-year; TTM through Dec 2025 was 1.57%, a 77.0% decrease, with the full-year FY2025 number at 13.26%, down 1247.0% from a year prior.
- Return on Sales hit 2.33% in Q4 2025 for Avalo Therapeutics, down from 2.26% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 0.93% in Q3 2024 to a low of 2.33% in Q4 2025.
- Median Return on Sales over the past 5 years was 0.13% (2023), compared with a mean of 0.45%.
- Biggest five-year swings in Return on Sales: soared 115bps in 2024 and later tumbled -319bps in 2025.
- Avalo Therapeutics' Return on Sales stood at 0.0% in 2021, then skyrocketed by 99bps to 0.0% in 2022, then plummeted by -382254bps to 0.14% in 2023, then crashed by -1187bps to 1.84% in 2024, then dropped by -26bps to 2.33% in 2025.
- The last three reported values for Return on Sales were 2.33% (Q4 2025), 2.26% (Q3 2025), and 1.84% (Q4 2024) per Business Quant data.